

Francesco Franchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1678711/publications.pdf>

Version: 2024-02-01

75
papers

3,407
citations

186265
28
h-index

144013
57
g-index

78
all docs

78
docs citations

78
times ranked

3521
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends in Cardiovascular Medicine, 2023, 33, 133-138. | 4.9 | 21 |
| 2 | Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 452-461. | 3.0 | 2 |
| 3 | Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 677-686. | 3.0 | 45 |
| 4 | Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. European Heart Journal, 2022, 43, 959-967. | 2.2 | 79 |
| 5 | Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. Thrombosis and Haemostasis, 2022, 122, 1341-1351. | 3.4 | 5 |
| 6 | Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 728-737. | 3.0 | 6 |
| 7 | Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2022, 15, 807-809. | 2.9 | 3 |
| 8 | Impact of the ABCD GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation. Clinical Pharmacology and Therapeutics, 2022, 112, 146-155. | 4.7 | 7 |
| 9 | Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715. | 4.7 | 25 |
| 10 | Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study. BMJ Open Diabetes Research and Care, 2021, 9, e001939. | 2.8 | 15 |
| 11 | Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor. Journal of Thrombosis and Thrombolysis, 2021, 51, 741-747. | 2.1 | 10 |
| 12 | Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet, The, 2021, 397, 1470-1483. | 13.7 | 133 |
| 13 | Genotype-Guided Antiplatelet Therapy in Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2021, 14, 751-753. | 2.9 | 2 |
| 14 | Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Review of Clinical Pharmacology, 2021, 14, 963-978. | 3.1 | 27 |
| 15 | Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization. International Journal of Cardiology, 2021, 345, 36-38. | 1.7 | 7 |
| 16 | Typical atrial flutter from blunt cardiac injury: an atypical cause. Journal of Geriatric Cardiology, 2021, 18, 155-157. | 0.2 | 0 |
| 17 | Pharmacodynamic profiles of aspirin versus dual-pathway inhibition with either aspirin or clopidogrel among patients with stable atherosclerotic disease. European Heart Journal Supplements, 2021, 23, . | 0.1 | 0 |
| 18 | Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. Thrombosis and Haemostasis, 2020, 120, 083-093. | 3.4 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical and Translational Science</i> , 2020, 13, 473-481. | 3.1 | 9 |
| 20 | Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 1500-1502. | 1.6 | 10 |
| 21 | Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. <i>Genetics in Medicine</i> , 2020, 22, 1898-1902. | 2.4 | 9 |
| 22 | <p>Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 217-226. | 0.7 | 14 |
| 23 | Clopidogrel drug interactions: a review of the evidence and clinical implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1079-1096. | 3.3 | 8 |
| 24 | Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. <i>JACC Basic To Translational Science</i> , 2020, 5, 419-428. | 4.1 | 18 |
| 25 | Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects inÂCoronary Artery Disease Patients Treated With Morphine. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1538-1549. | 2.9 | 26 |
| 26 | Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071986147. | 2.5 | 3 |
| 27 | Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537. | 2.9 | 366 |
| 28 | Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-SegmentâElevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 139, 1661-1670. | 1.6 | 106 |
| 29 | Pharmacodynamic Effects of VorapaxarÂin PatientsÂWith and WithoutÂDiabetes Mellitus. <i>JACC Basic To Translational Science</i> , 2019, 4, 763-775. | 4.1 | 12 |
| 30 | Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y ₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e011139. | 3.7 | 33 |
| 31 | Switching Oral Anticoagulant Therapy inÂPatients With Atrial Fibrillation Undergoing Percutaneous CoronaryÂIntervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2342-2345. | 2.9 | 1 |
| 32 | Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> GenotypeâEGuided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 664-674. | 4.7 | 94 |
| 33 | Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 478-490. | 3.1 | 61 |
| 34 | Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Translational Medicine</i> , 2018, 16, 92. | 4.4 | 41 |
| 35 | Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease. <i>Circulation</i> , 2018, 137, 2450-2462. | 1.6 | 46 |
| 36 | The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACSÂPatients Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1243-1245. | 2.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 23-37. | 2.0 | 17 |
| 38 | Role of genetic testing in patients undergoing percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 151-164. | 3.1 | 57 |
| 39 | The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. <i>Expert Review of Hematology</i> , 2018, 11, 5-12. | 2.2 | 17 |
| 40 | Diabetes and antiplatelet therapy: from bench to bedside. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 594-609. | 1.7 | 45 |
| 41 | Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 1301-1303. | 1.6 | 2 |
| 42 | Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496. | 13.7 | 180 |
| 43 | Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y ₁₂ Receptor Inhibitors. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 130-132. | 2.9 | 7 |
| 44 | Antithrombotic therapy for patients with STEMI undergoing primary PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 361-379. | 13.7 | 76 |
| 45 | Switching P2Y ₁₂ Receptor Inhibiting Therapies. <i>Interventional Cardiology Clinics</i> , 2017, 6, 67-89. | 0.4 | 10 |
| 46 | Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, . | 3.7 | 30 |
| 47 | Institutional profile: University of Florida Health Personalized Medicine Program. <i>Pharmacogenomics</i> , 2017, 18, 421-426. | 1.3 | 64 |
| 48 | International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor-Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975. | 1.6 | 293 |
| 49 | In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y ₁₂ Receptor-Mediated Signaling in Ticagrelor-Treated Patients. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1374-1375. | 2.9 | 8 |
| 50 | De-Escalation of Platelet P2Y ₁₂ Receptor Inhibiting Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2571-2573. | 2.9 | 5 |
| 51 | Switching from ticagrelor to clopidogrel: New answers and further questions. <i>Thrombosis and Haemostasis</i> , 2017, 117, 207-208. | 3.4 | 3 |
| 52 | Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y ₁₂ receptor inhibitors. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1060-1069. | 3.4 | 8 |
| 53 | Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2016, 134, 780-792. | 1.6 | 82 |
| 54 | Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1089-1098. | 2.9 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1994-2004. | 2.8 | 104 |
| 56 | Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 228-230. | 2.9 | 1 |
| 57 | Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. <i>Journal of the American College of Cardiology</i> , 2016, 67, 603-613. | 2.8 | 41 |
| 58 | A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. <i>European Heart Journal</i> , 2016, 37, 2722-2730. | 2.2 | 52 |
| 59 | Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1145-1154. | 2.8 | 108 |
| 60 | A Safety Evaluation of Cangrelor in Patients Undergoing PCI. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 275-285. | 2.4 | 12 |
| 61 | Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 321-334. | 4.9 | 3 |
| 62 | Switching P2Y ₁₂ -receptor inhibitors in patients with coronary artery disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 11-27. | 13.7 | 154 |
| 63 | Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 118-125. | 2.1 | 15 |
| 64 | Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. <i>Future Cardiology</i> , 2015, 11, 547-564. | 1.2 | 17 |
| 65 | Defining the Link Between Chronic Kidney Disease, High Platelet Reactivity, and Clinical Outcomes in Clopidogrel-Treated Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002760. | 3.9 | 11 |
| 66 | Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1075-1083. | 2.9 | 5 |
| 67 | Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1457-1467. | 2.9 | 71 |
| 68 | Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 267-277. | 3.1 | 22 |
| 69 | Novel antiplatelet agents in acute coronary syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 30-47. | 13.7 | 299 |
| 70 | Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. <i>Current Opinion in Cardiology</i> , 2014, 29, 553-563. | 1.8 | 8 |
| 71 | Pharmacodynamic Effects of Cangrelor on Platelet P2Y ₁₂ Receptor-Mediated Signaling in Prasugrel-Treated Patients. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 426-434. | 2.9 | 28 |
| 72 | Impaired Responsiveness to the Platelet P2Y ₁₂ Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1005-1014. | 2.8 | 155 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Platelet Function Testing in Contemporary Clinical and Interventional Practice. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 300. | 0.9 | 34 |
| 74 | Abstract 16668: The Effects of Dabigatran on Fibrin Network Structure and Lysis: A Simple Technique to Monitor Efficacy of Treatment?. Circulation, 2014, 130, . | 1.6 | 0 |
| 75 | Cangrelor: a review on pharmacology and clinical trial development. Expert Review of Cardiovascular Therapy, 2013, 11, 1279-1291. | 1.5 | 52 |